Wilfried R.
- Country
- Austria
- Department
- Haematology
Research Overview
- Phase III Trial of ARI0002h CAR T-Cell Therapy versus Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
- Phase 2 Multicohort Evaluation of Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone in Systemic AL Amyloidosis with Cardiac Involvement
- Evaluation of Minimal Residual Disease Techniques in Untreated Multiple Myeloma with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone Therapy
Data & Insights
Has run more than one trial at 120 of 254 partner sites.
Specializations
Multiple Myeloma Research
This investigator specializes in researching multiple myeloma treatments, with particular focus on novel therapeutic combinations and emerging cellular therapies. Their work encompasses both newly diagnosed cases and relapsed/refractory disease states.
- Daratumumab-based combination therapies
- Ciltacabtagene autoleucel therapy
- Stem cell transplantation approaches
The research extends to evaluating maintenance therapies and treatment strategies for various stages of myeloma progression.
Amyloidosis Studies
The investigator conducts extensive research in AL amyloidosis, focusing on innovative treatment approaches for both newly diagnosed and previously treated patients.
- Cardiac safety in AL amyloidosis
- Novel therapeutic combinations
- Treatment strategies for Mayo Stage IV patients
Their work includes evaluation of targeted therapies and their impact on patient outcomes in systemic amyloidosis.
Emerging Therapeutics
The investigator explores novel therapeutic agents and their applications in hematologic malignancies, with emphasis on targeted and immunotherapeutic approaches.
- BCMA-targeted therapies
- Monoclonal antibody treatments
- Combination therapy optimization
Research includes investigation of innovative drug combinations and their effectiveness in treatment-resistant cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.